found Documents:83

2018 Full Year Results

1 item

Announcement released: 7am BST (3pm HKT / 3am EDT) >> See announcement here Presentation webcast & call: 9am BST (5pm HKT / 5am EDT) >> Click here for the webcast US conference call: 9am EDT (1pm BST/9pm HKT

Download Presentation (PDF)

Presentations | 4 Mar 2019

Clin Cancer Res: Surufatinib in advanced, well-differentiated neuroendocrine tumors

Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, 3 single-arm, open-label, phase Ib/II trial Jianming Xu, Jie Li, Chunmei Bai, Nong Xu, Zhiwei Zhou, Zhiping Li, Caicun Zhou, Ru Jia, Ming Lu, Yuejuan Cheng, Chenyu Mao

Event, Presentations | 7 Jan 2019

37th Annual J.P. Morgan Healthcare Conference

1 item

Location: Westin St. Francis Hotel, San Francisco, CA Presentation Date: Wednesday Jan 9, 2019 Presentation Time: 9:30am PST (12:30pm EST/5:30pm BST) Audio Recording: Please download the accompanying presentation. [audio m

Download Presentation (PDF)

Event, Presentations | 27 Jul 2018

2018 Half-Year Financial Results

1 item

Announcement released: 7am BST (2pm HKT/2am EDT) >> See announcement here Presentation webcast & call: 9am BST (4pm HKT/4am EDT) >> Click here for the webcast US conference call: 9am EDT (2pm BST/9

Download Presentation (PDF)

Presentations | 26 Jun 2018

JAMA: Fruquintinib vs Placebo in Previously Treated Metastatic Colorectal Cancer

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial Jin Li; Shukui Qin; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Lei Yang; Yanhong Deng;

Presentations | 4 Jun 2018

ASCO 2018: Colorectal cancer Q-TWiST with fruquintinib treatment in FRESCO

Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer treated with fruquintinib in FRESCO Presenter: Yu-Xian Bai Other Authors: Hongyan Li, Ning Wang, Xiaojun Guo, Wei Wang, Songhua F

Presentations | 4 Jun 2018

ASCO 2018: Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO

Presenter: Ruihua Xu Other Authors: Jin Li, Yu-Xian Bai, Yanhong Deng, Lei Yang, Haijun Zhong, Zhendong Chen, Hongming Pan, Weijian Guo, Yongqian Shu, Ying Yuan, Jianming Xu, Lin Shen, Ning Wang, Xin Wang, Haidong Chi, Jack Peng, Y

Presentations | 17 Apr 2018

AACR 2018: MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib

4541 / 26 - MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor Presenter/Authors M. M. Frigault1, S. Signoretti2, A. Markovets

Presentations | 23 Mar 2018

ASCPT 2018: Fruquintinib Pharmacokinetics in Humans

1 item

Pharmacokinetics of Fruquintinib in Humans Venue: American Society for Clinical Pharmacology & Therapeutics Annual Meeting in Orlando, Florida, USA Abstract #: PII-116 Authors: Ke Li, Chen Yu, Yanmei Liu, Xiangkun Li, Sumei Xia, Jian Wa

Download Poster Presentation (PDF)

Event, Presentations | 12 Mar 2018

2017 Full Year Financial Results

1 item

Announcement released: 7am BST (3pm HKT/3am EDT) » See announcement here Presentation webcast & call: 9am BST (5pm HKT/5am EDT) » Click here for a video of the webcast US conference call: 9am EDT (1pm BST/9pm HKT)

View Presentation (PDF)

Presentations | 12 Mar 2018

Journal of Clinical Oncology: Phase II Trial of Fruquintinib in Patients with Advanced Nonsquamous NSCLC

Shun Lu, Jianhua Chang, Xiaoqing Liu, Jianhua Shi, You Lu, Wei Li, Jin-ji Yang, Jianying Zhou, Jie Wang, Tongtong An, Lei Yang, Zhe Liu, Xiangdong Zhou, Mo Chen, Ye Hua and Weiguo Su Abstract Purpose Patients with advanced non‒small-cell lung

Presentations | 24 Feb 2018

ACOS 2018: Adverse Events of Special Interest Profiles and Time Courses of Fruquintinib in the FRESCO Trial

1 item

Venue: The 13th International Conference of the Asian Clinical Oncology Society in Chiang Mai, Thailand Abstract #: ABS093 Authors: Jin Li, Shukui Qin, Yuxian Bai, Yanhong Deng, Lei Yang, Zhendong Chen, Haijun Zhong, Rui-hua Xu, Hongming Pan,

Download Slides (PDF)

Presentations | 20 Feb 2018

ICTO2018: Phase Ib of Savolitinib and Durvalumab in Renal Cell Carcinoma (CALYPSO)

A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Savolitinib in Patients with Metastatic Renal Cell Carcinoma S Vari1, B Szabados1, A GomezdeLiano1, K Mousa2, L Rammazzo2, A Prendergast2, T Powles1 1 Barts Health NHS Trust, Barts Can

Presentations | 17 Oct 2017

WCLC 2017: Phase Ib/II savolitinib plus Iressa® in MET-driven NSCLC

OA 09.06 – A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC Jin-Ji Yang, Jian Fang, Y. Shu, J. Chang, G. Chen, J. He, W. Li, X. Liu, N. Yang, Caicun Zhou, J. Huang, L. Yang, A.A. Han

Presentations | 17 Oct 2017

WCLC 2017: Phase Ib/II savolitinib plus Tagrisso® in MET-driven NSCLC

OA 09.03 – TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI Myung-Ju Ahn, Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. T

Presentations | 15 Oct 2017

WCLC 2017: Phase II fruquintinib combination with Iressa in NSCLC

JCSE 01.12 – A Phase II study of fruquintinib in combination with gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations (NCT02976116) Shun Lu, Jianying Zhou, Xiaomin Niu, Mo Chen, Hongyan Yin, Ye Hua, Weiguo Su Venue: IA

Presentations | 28 Sep 2017

CSCO 2017: Savolitinib Phase Ib in c-MET Gastric Cancer

1 item

Phase Ib Trial of the Safety and Antitumor Activity of Savolitinib in Advanced Gastric Cancer Patients with Aberrant c-MET Jifeng Feng, Baorui Liu, Tianshu Liu, Nong Xu, Jianming Xu, Yunpeng Liu, Yuxian Bai, Jin Li, Wei Li, Chunmei Bai, Tao Zhang,

Download Slides (PDF)

Presentations | 28 Sep 2017

CSCO 2017: Theliatinib Phase I Results

1 item

Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial Lin Shen, Li Zhang, Hongyun Zhao, Wenfeng Fang, Jifang Gong Venue: Chinese Society of Clinical Oncology Annual Meeting Session: Esophageal Cancer Presenter: Jif

Download Slides (PDF)

Presentations | 27 Sep 2017

CSCO 2017: FRESCO In-Depth Analysis

1 item

In-depth Analysis of the FRESCO Study: a Randomized, Double-blind, Phase III Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients with 3+ Line Advanced Colorectal Cancer Shukui QIN*, Jin LI*, Yuxian BAI, Yanhong DENG, Lei YANG, Zhen

Download Slides (PDF)

Presentations | 27 Sep 2017

CSCO 2017: Theliatinib Preclinical Study in Esophageal Cancer

Is EGFR a “feasible” target for advanced esophageal cancer treatment? Rongxin Ren, Shiming Fan, Linfang Wang,Min Cheng, Dongxia Shi, Wei Zhang,Renxiang Tang, Ying Yu, Longxian Jiao, Jun Ni, Haibin Yang, Huaqing Cai,Feng Zhou, Weihan Zhang, Wei

Event, Presentations | 16 Sep 2017

The Royal Society of Medicine 15th Medical Innovations Summit

1 item

The Royal Society of Medicine, London, UK Please visit rsm.ac.uk for more information. A video recording of the 20-minute presentation is available. RSM video link Note: there is a 25-second audio error at 2:55.

View Presentation (PDF)

Event, Presentations | 31 Jul 2017

2017 Half-Year Financial Results

1 item

Announcement released: 7am BST (2am EDT, 2pm HKT) » See announcement here Presentation webcast & call: 9am BST (4pm HKT) » click here for a video of the webcast US conference call: 9am EDT (2pm BST) » To parti

View Presentation (PDF)

Presentations | 23 Jun 2017

Journal of Clinical Oncology: Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced PRCC

Toni K. Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, Eric Jonasch, Daniel Y.C. Heng, Thomas Powles, Melanie M. Frigault, Edwin A. Clark, Amir A. Handzel, Humphrey Gardner, Shethah Morgan, Laurence Albiges, and Sumanta Kumar Pal Abstract Pur

Event, Presentations | 21 Jun 2017

Bernstein Conference: China Oncology Day

1 item

Mandarin Oriental, Hong Kong

Download Presentation (PDF)

Presentations | 5 Jun 2017

ASCO 2017: Fruquintinib Phase III in Metastatic Colorectal Cancer (FRESCO)

1 item

A randomized, double-blind, placebo-controlled, multi-centered phase III trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO) Venue: American Society of Clinical Oncol

View Presentation Slides (PDF)

Presentations | 5 Jun 2017

ASCO 2017: Sulfatinib Phase II in Medullary and Differentiated Thyroid Cancer

1 item

A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) Venue: American Society of Clinical Oncology Annual Meeti

Download Poster Presentation (PDF)

Presentations | 4 Apr 2017

AACR 2017: Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases

1 item

Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases Authors: Jinghong Zhou, Jun Ni, Min Cheng, Na Yang, Junqing Liang, Liang Ge, Wei Zhang, Jianxing Tang, Qiaoling Sun, Fu Li, Jia Hu,

Download Presentation (PDF)

Presentations | 3 Apr 2017

AACR 2017: Fruquintinib combinations with targeted therapies or immune checkpoint inhibitors in preclinical tumor models

1 item

Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models Authors: Yongxin Ren, Qiaoling Sun, Jingwen Long, Shiming Fan, Renxiang Tang,

Download Presentation (PDF)

Event, Presentations | 30 Mar 2017

R&D Briefing for Investors 2017

1 item

Introduction The Future of Targeted Cancer Therapy In Lung Cancer Post-POC Portfolio Pre-POC Portfolio Research Strategy Transforming into a Fully Integrated Global Biopharma Wed. Mar 29, 9:30am - South Place Hotel, London, UK

Download Presentation (PDF)

Event, Presentations | 13 Mar 2017

2016 Full Year Financial Results

1 item

Announcement released: 7am GMT » See announcement here Webcast presentation & conf call: 9am GMT (5pm HKT) » click here for a video of the webcast (available for six months) » To participate by phone, please u

View Presentation (PDF)

Presentations | 9 Mar 2017

ENETS 2017: Sulfatinib Phase Ib/II in Advanced Neuroendocrine Tumors

1 item

An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) Authors: J.M. Xu, J. Li, C.M. Bai, N. Xu, Z.W. Zhou, Z.P. Li, C.C. Zhou, W. Wang, J. Li, C. Qi, Y. Hua, W.G. Su Summary: The current Phase

Download Presentation (PDF)

Presentations | 18 Feb 2017

ASCO GU 2017: Savolitinib Phase II in advanced papillary renal cell cancer

1 item

A Single-Arm Biomarker-Based Phase II Trial of Savolitinib in Patients with Advanced Papillary Renal Cell Cancer Toni K. Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, Eric Jonasch, Daniel Y. C. Heng, Thomas Powles, Melanie M. Frigault, Edwi

Download Poster Presentation (PDF)

Presentations | 1 Feb 2017

Oncotarget: Sulfatinib Phase I Results

Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study Authors: Jian Ming Xu, Yan Wang, Yu Ling Chen, Ru Jia, Jie Li, Ji Fang Gong, Jing Li, Chuan Qi, Ye Hua, Cui Rong Tan, Jian Wang, Ke

Presentations | 20 Jan 2017

ASCO GI 2017: Fruquintinib in Combination with Paclitaxel in 2L Gastric Cancer

1 item

A Phase I/II Trial of Fruquintinib in Combination with Paclitaxel for Second-line Treatment in Patients with Advanced Gastric Cancer Ruihua Xu, Dongsheng Zhang, Lin Shen, Jin Li, Jing Huang, Yang Zhang, Jifang Gong, Weijian Guo, Songhua Fan, Ke Li,

View Presentation Poster (PNG)

Presentations | 19 Jan 2017

Journal of Hematology & Oncology: fruquintinib Phase Ib & Phase II in colorectal cancer

Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study Authors: Rui-Hua Xu, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin She

Presentations | 6 Dec 2016

WCLC 2016: Fruquintinib Phase II Study in Advanced NSCLC

1 item

A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer (NCT02590965) Shun Lu1, Jianhua Chang2, XiaoQing Liu3, Jianhua Shi4, You Lu5, Wei Li6, Jinji Yang7, Jianying Zhou8, Jie Wa

View Presentation (PDF)

Presentations | 6 Dec 2016

ASH 2016: Syk Inhibitor HMPL-523 Anti-tumor Activity in vitro and in vivo

1 item

HMPL-523, a Novel SYK Inhibitor, Showed Anti-tumor Activities in Vitro and in Vivo Na Yang, Wei Deng, Qiaoling Sun, Junqing Liang, Linfang Wang, Shiming Fan, Renxiang Tang, Ying Yu, Junen Sun, Feng Zhou, Guangxiu Dai, Yongxin Ren, Weiguo Qing and We

View Poster Presentation (PDF)

Presentations | 5 Dec 2016

WCLC 2016: Epitinib in EGFRm+ NSCLC Patients with Brain Metastasis

1 item

A Phase Ib study of Epitinib to evaluate efficacy and safety in EGFR mutation positive (EGFRm+) NSCLC patients with brain metastasis Qing Zhou1, Bin Gan1, Qunying Hong2, Mengzhao Wang3, XiaoQing Liu4, Liwei Yuan5, Ye Hua5, Hongcan Ren5, Weiguo Su5,

View Poster Presentation (PNG)

Presentations | 14 Nov 2016

ACR 2016: Phase I Dose Escalating Study of HMPL-523 in Australian Male Healthy Subjects

1 item

A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of HMPL-523 in Australian Male Healthy Subjects Background: S

View Presentation Poster (PNG)

Event, Presentations | 25 Aug 2016

CLSA Investors' Forum

1 item

Hong Kong

View Presentation (PDF)

Event, Presentations | 2 Aug 2016

2016 Half-Year Financial Results

1 item

Announcement released: 7am BST » See announcement here Webcast presentation & conf call: 9am BST (4pm HKT) » click here for a video of the webcast (available for six months) » To participate in the call, please

View Presentation Slides (PDF)

Presentations | 3 Jun 2016

ASCO 2016: Safety profile and preliminary clinical efficacy of epitinib in EGFRm+ NSCLC

The safety profile of a selective EGFR TKI epitinib (HMPL-813) in patients with advanced solid tumors and preliminary clinical efficacy in EGFRm+ NSCLC patients with brain metastasis Authors: Qing Zhou, Bin Gan, Liwei Yuan, Ye Hua, Yi-Long Wu Ba

Presentations | 3 Jun 2016

ASCO 2016: Preliminary results of a phase Ib trial of savolitinib combined with gefitinib in EGFR-mutant lung cancer

Authors: Jin-Ji Yang, Liu Yang, Andrew Farnsworth, Amir Handzel, Tanya Coleman, Shethah Morgan, Yi-Long Wu Background: Savolitinib (AZD6094, volitinib, HMPL-504) is a potent & selective small molecule MET inhibitor. In preclinical models the c

Presentations | 16 Apr 2016

AACR 2016: Activity of Savolitinib against MET Ex14 mutations and resistance to METi through decoupling from MYC expression

1 item

Abstract (please download the poster for full details) Authors: Evan Barry, Ryan Henry, Alexandra Borodovsky, Elizabeth Maloney, Brendon Ladd, Melanie Frigault, Michael Zinda, Edwin Clark, Alwin Schuller and Celina D’Cruz Alterations in the

View Poster (PDF)

Presentations | 1 Mar 2016

2015 Full Year Results Presentation

1 item

View Presentation (PDF)

Presentations | 7 Nov 2015

EORTC 2015: Synergistic effect of c-Met inhibitor Savolitinib in combination with a VEGFR inhibitor Fruquintinib in clear cell renal cell carcinoma xenograft models

1 item

Abstract (please download the poster for full details): Authors: Yongxin Ren, Shiming Fan, Yunxin Chen, Renxiang Tang, Wei Zhang, Jianxing Tang, Linfang Wang, Dongxia Shi, Hongbo Chen, Min Cheng, Weiguo Qing, Weiguo Su Renal cell carcinoma (RCC

View Poster (PDF)

Presentations | 6 Nov 2015

EORTC 2015: First-in-human phase I study of selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors

1 item

Abstract (download poster for full details): Authors: Jian-Ming Xu, Lin Shen, Yan Wang, Yu-ling Chen, Ru Jia, Jian Wang, Ke Li, Yang Sai, Jing Li, Chuan Qi, Hua Ye, Su Weiguo Background: Sulfatinib is a highly selective oral small molecule inhi

View Poster (PDF)

Presentations | 27 Sep 2015